CME
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
Host: Allison Betof Warner, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 co